Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Covance Inc. (CVD), PAREXEL International Corporation (PRXL): Outsourcing Your Laboratory

The increasing cost of drug development coupled with long delays in regulatory approvals has made R&D a daunting task for small drug developers. This has opened up a new business opportunity in the form of contract research organizations, or CROs — where companies can outsource their R&D department at a fraction of what it would cost to develop a drug in-house.

Covance Inc. (NYSE:CVD)CROs now offer end-to-end research and development support starting right from drug discovery and going all the way to marketing support. New Jersey-based Covance Inc. (NYSE:CVD) is a leading CRO offering contract research services to leading pharma and medical device companies. Covance Inc. (NYSE:CVD)’s stock price has jumped 76% in trading in the last 12 months, reflecting the boom in this interesting business segment.

Services offerings
Covance Inc. (NYSE:CVD) essentially operates through two segments: early-stage and late-stage drug development. Early-stage development includes support services for discovery, preclinical, and clinical services. Late-stage development includes central laboratory, clinical development (phase 2-4), and market access services.

Late-stage development services represent a major earnings driver for the company. At this stage, most developing biotechs with true potential — the ones that reach the later clinical phases — are flush with cash from external funding and other sources.

The company has strong alliances with leading companies in various research areas. It has a 10-year agreement with Sanofi amounting to $1.2 billion-$2.2 billion for early- and late-stage drug development, a $1.6 billion late-stage development program with Eli Lilly for 10 years, and a $42 million agreement with Kellogg for nutritional chemistry services. It also had alliances with Merck for genome analysis.

Opportunity for Covance in the CRO market
The industry is highly fragmented with many participants including small and medium players, despite being dominated by several high-profile companies. It ranges from large companies like Covance Inc. (NYSE:CVD) to small specialty firms. With increasing demand for novel therapies, especially in the orphan drug market where R&D costs are necessarily higher, companies have a growing need for lower-cost research. Overall, total spending on R&D is $150 billion — including $75 billion for drug development, $40 billion for drug research, and $40 billion in other segments. The outsourcing research market is experiencing growth in the specialty segment as drug and medical devices manufacturers are pouring their funds into it.

Covance Inc. (NYSE:CVD) also generates 20% of its revenue from non-traditional activities like drug discovery, drugs R&D, post-R&D, and other adjacent markets. High penetration and strong focus on non-traditional businesses will provide more support for revenue growth in the future. Covance can capture a larger market share by focusing on the specialty segment and growing into the animal health and medical devices market.

Stable financial performance
Covance’s early stage and late-stage business segments represent 40% and 60% of total revenue, respectively. Early stage services showed low growth compared to late-stage development services.

In the recent quarter that ended on June 30, late-stage services posted a 17% year-over-year growth to $378 million. The growth was driven by increased volume in central laboratories and revenue from clinical development. Early-stage revenue remained flat, and overall services revenues for the company were $592.3 million, an increase of 9.1% over the prior year. As of June 30, the company’s adjusted net book-to-bill was 1.31 times adjusted net orders of $776 million, and backlog was $6.73 billion.

The company’s bottom line also demonstrated significant growth in the recent quarter. At the end of the quarter, Covance is financially strong with cash balance of $446 million.

Based on the current trend across its business segments, the company should experience modest growth in early-stage development services and expects to generate around $860 million-$870 million in annual revenue between 2013 and 2015. Late-stage product development services continue to drive the company’s top line performance. It is expected that the company will generate revenue of $1.5 billion-$1.7 billion annually between 2013 and 2015.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.